Enliven reports Q1 net loss, $452M runway and H2 2026 Phase 3 start
Enliven reported Q1 net loss of $23.6 million and R&D expenses of $20.7 million, compared with $28.5 million net loss and $24.9 million R&D a year earlier. The company holds $452.4 million cash into H1 2029 and plans mid-2026 Phase 1 data and H2 2026 Phase 3 start for ELVN-001.
1. Program Highlights
ELVN-001 is a potent, highly selective ATP-competitive inhibitor targeting the BCR::ABL gene fusion in chronic myeloid leukemia. Positive initial Phase 1b data were reported in January, and enrollment continues in the 80 mg once-daily expansion cohort for previously treated CML patients.
2. Financial Results
For the quarter ended March 31, 2026, Enliven recorded $20.7 million in R&D expenses and $7.1 million in G&A expenses, resulting in a net loss of $23.6 million. The company held $452.4 million in cash, cash equivalents and marketable securities at quarter end.
3. Upcoming Milestones
Enliven plans to present additional Phase 1 data by mid-2026, engage with the FDA on dose selection and Phase 3 trial design, and initiate the pivotal Phase 3 ENABLE-2 trial in the second half of 2026.